# Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

> **NCT01516983** · PHASE1,PHASE2 · COMPLETED · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** icotinib
- **RADIATION:** Whole brain radiotherapy

## Key facts

- **NCT ID:** NCT01516983
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516983, "Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01516983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*